A Phase III Study Evaluating the Efficacy and Safety of Satavaptan Versus Placebo in Patients With Dilutional Hyponatremia

Exclusion Criteria

• •Presence of clinical signs of hypovolemia (e.g. orthostatic decreases in blood pressure and increase in pulse rate, dry mucus membranes, decreased skin turgor)
• •Presence of clinical signs of hypervolemia (e.g. generalized edema, jugular venous extension)
• •Participants with adrenocortical insufficiency
• •Participants with hypothyroidism
• •Participants with known causes of transient SIADH
• •Participants with psychogenic polydipsia or beer potomania
• •Concomitant use of thiazide diuretics during the study
• •Presence of uncontrolled diabetes with fasting blood glucose ≥200 mg/dL (≥11.09 mmol/L) at time of screening
• •Participants with impaired hepatic function or liver cirrhosis (Child-Pugh A-C)
• •Pregnant or breast-feeding women
• •The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.